Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees

PLoS Pathogens

Volumn 8, Issue 8, 2012, Pages

  Morin, Trevor J ^a,e   Broering, Teresa J ^a   Leav, Brett A ^a   Blair, Barbra M ^a,f,g   Rowley, Kirk J ^a   Boucher, Elisabeth N ^a   Wang, Yang ^a   Cheslock, Peter S ^a   Knauber, Michael ^a   Olsen, David B ^b   Ludmerer, Steve W ^b   Szabo, Gyongyi ^a   Finberg, Robert W ^a   Purcell, Robert H ^c   Lanford, Robert E ^d   Ambrosino, Donna M ^a,h   Molrine, Deborah C ^a   Babcock, Gregory J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

^e University of California Santa Cruz   (United States)

^f MOUNT AUBURN HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h VISTERRA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY HCV1; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; IN VITRO STUDY; NONHUMAN; OUTCOME ASSESSMENT; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD81; CELL LINE; DISEASE MODELS, ANIMAL; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; LIVER TRANSPLANTATION; MUTATION; NEUTRALIZATION TESTS; PAN TROGLODYTES; RNA, VIRAL; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

HEPATITIS C VIRUS; PAN;

EID: 84866152584     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002895     Document Type: Article

References (55)

1. Lavanchy D, (2009) The global burden of hepatitis C. Liver Int 29: 74-81.
2. Shepard CW, Finelli L, Alter MJ, (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567.
3. Alter HJ, Seeff LB, (2000) Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 20: 17-35.
4. Makris M, Preston FE, Rosendaal FR, Underwood JC, Rice KM, et al. (1996) The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 94: 746-752.
5. Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, et al. (2003) Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 39: 389-396.
6. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, et al. (2005) Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42: 255-262.
7. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, et al. (2005) Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 41: 289-298.
8. Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, et al. (2011) PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 17: 528-538.
9. Knodell RG, Conrad ME, Ginsberg AL, Bell CJ, (1976) Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet 1: 557-561.
10. Sanchez-Quijano A, Pineda JA, Lissen E, Leal M, Diaz-Torres MA, et al. (1988) Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet 1: 1245-1249.
11. Piazza M, Sagliocca L, Tosone G, Guadagnino V, Stazi MA, et al. (1998) Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med 157: 1537-1544.
12. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, et al. (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 104: 6025-6030 Epub 2007 Mar 6028.
13. Davis GL, (2006) Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills? Liver Transpl 12: 1317-1319.
14. Schiano TD, Charlton M, Younossi Z, Galun E, Pruett T, et al. (2006) Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 12: 1381-1389.
15. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, et al. (1993) Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329: 1842-1847.
16. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, et al. (1991) Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 13: 619-626.
17. Feray C, Gigou M, Samuel D, Ducot B, Maisonneuve P, et al. (1998) Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 128: 810-816.
18. Op De Beeck A, Cocquerel L, Dubuisson J, (2001) Biogenesis of hepatitis C virus envelope glycoproteins. J Gen Virol 82: 2589-2595.
19. Bartosch B, Dubuisson J, Cosset FL, (2003) Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197: 633-642.
20. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, et al. (2003) Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 100: 7271-7276 Epub 2003 May 7221.
21. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, et al. (1998) Binding of hepatitis C virus to CD81. Science 282: 938-941.
22. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, et al. (2007) Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446: 801-805.
23. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, et al. (2009) Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457: 882-886.
24. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, et al. (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. Embo J 21: 5017-5025.
25. von Hahn T, Rice CM, (2008) Hepatitis C virus entry. J Biol Chem 283: 3689-3693 Epub 2007 Sep 3619.
26. Broering TJ, Garrity KA, Boatright NK, Sloan SE, Sandor F, et al. (2009) Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol 83: 12473-12482 Epub 12009 Sep 12416.
27. Blair B, Babcock G, Szabo G, Finberg R, Cheslock P, et al. (2009) Human Monoclonal Antibodies Directed Against the E2 Glycoprotein of Hepatitis C Virus (HCV) Prevents Infection in Chimpanzees [Abstract 1048]. In: Proceedings of the 44th Annual Meeting of the European Association for the Study of the Liver; 22-26 April 2009; Copenhagen, Denmark. EASL 2009. Available: http://www.kenes.com/easl2009/posters/Abstract48.htm.
28. Tarr AW, Owsianka AM, Jayaraj D, Brown RJ, Hickling TP, et al. (2007) Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J Gen Virol 88: 2991-3001.
29. Bukh J, Meuleman P, Tellier R, Engle RE, Feinstone SM, et al. (2010) Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J Infect Dis 201: 1381-1389.
30. Krawczynski K, Alter MJ, Tankersley DL, Beach M, Robertson BH, et al. (1996) Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 173: 822-828.
31. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, et al. (1994) Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 91: 7792-7796.
32. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, et al. (1996) Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 93: 15394-15399.
33. Sanchez-Fueyo A, Restrepo JC, Quinto L, Bruguera M, Grande L, et al. (2002) Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 73: 56-63.
34. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR, (2002) The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122: 889-896.
35. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, et al. (2002) Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 36: 202-210.
36. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, et al. (1999) European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 117: 619-625.
37. Gane E, (2003) The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 9: S28-34.
38. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, et al. (1999) High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 29: 250-256.
39. Velidedeoglu E, Mange KC, Frank A, Abt P, Desai NM, et al. (2004) Factors differentially correlated with the outcome of liver transplantation in hcv+ and HCV- recipients. Transplantation 77: 1834-1842.
40. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, et al. (1996) Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 334: 815-820.
41. Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, et al. (2009) Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl 15: 1872-1881.
42. Berenguer M, (2008) Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 49: 274-287.
43. Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu MY, et al. (2007) Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A 104: 8449-8454.
44. Zhang P, Zhong L, Struble EB, Watanabe H, Kachko A, et al. (2009) Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A 106: 7537-7541.
45. Tarr AW, Urbanowicz RA, Jayaraj D, Brown RJ, McKeating JA, et al. (2012) Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol 86: 2739-2749.
46. Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, et al. (2005) High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 280: 7793-7799.
47. Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, et al. (2006) High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 281: 18285-18295.
48. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, et al. (2005) Complete replication of hepatitis C virus in cell culture. Science 309: 623-626.
49. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796.
50. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102: 9294-9299.
51. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, et al. (2006) Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 103: 3805-3809.
52. Keck ZY, Xia J, Cai Z, Li TK, Owsianka AM, et al. (2007) Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol 81: 1043-1047.
53. Helle F, Vieyres G, Elkrief L, Popescu CI, Wychowski C, et al. (2010) Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol 84: 11905-11915.
54. Liu S, McCormick KD, Zhao W, Zhao T, Fan D, et al. (2012) Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. Hepatology 2012: 25665.
55. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, et al. (1997) Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277: 570-574.